See more : Public Joint Stock Company Pavlovo Bus (PAZA.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Enfusion, Inc. (ENFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enfusion, Inc., a leading company in the Software – Application industry within the Technology sector.
- Daré Bioscience, Inc. (DARE) Income Statement Analysis – Financial Results
- The Planting Hope Company Inc. (MYLK.V) Income Statement Analysis – Financial Results
- SBW, Inc. (102280.KS) Income Statement Analysis – Financial Results
- Ciena Corporation (CIE1.DE) Income Statement Analysis – Financial Results
- Dianomi plc (DNM.L) Income Statement Analysis – Financial Results
Enfusion, Inc. (ENFN)
About Enfusion, Inc.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 174.54M | 150.35M | 111.70M | 79.57M | 59.03M |
| Cost of Revenue | 57.64M | 47.10M | 31.85M | 21.36M | 16.96M |
| Gross Profit | 116.89M | 103.25M | 79.86M | 58.21M | 42.07M |
| Gross Profit Ratio | 66.97% | 68.67% | 71.49% | 73.16% | 71.27% |
| Research & Development | 19.89M | 17.16M | 153.40M | 6.32M | 4.15M |
| General & Administrative | 64.64M | 68.76M | 150.61M | 35.89M | 16.63M |
| Selling & Marketing | 20.42M | 29.29M | 51.73M | 9.93M | 7.43M |
| SG&A | 85.05M | 98.05M | 202.34M | 45.82M | 24.05M |
| Other Expenses | 0.00 | -638.00K | -1.19M | 82.00K | -3.00K |
| Operating Expenses | 104.95M | 115.21M | 355.74M | 52.13M | 28.20M |
| Cost & Expenses | 162.59M | 162.31M | 387.58M | 73.49M | 45.16M |
| Interest Income | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Interest Expense | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Depreciation & Amortization | 9.99M | 6.60M | 3.98M | 2.29M | 1.16M |
| EBITDA | 21.94M | -5.62M | -271.91M | 8.37M | 15.02M |
| EBITDA Ratio | 12.57% | -3.74% | -244.49% | 10.62% | 25.45% |
| Operating Income | 11.95M | -11.96M | -275.88M | 6.07M | 13.87M |
| Operating Income Ratio | 6.85% | -7.96% | -246.99% | 7.63% | 23.50% |
| Total Other Income/Expenses | -464.00K | -225.00K | -5.78M | -1.58M | -727.00K |
| Income Before Tax | 11.48M | -12.19M | -281.66M | 4.49M | 13.14M |
| Income Before Tax Ratio | 6.58% | -8.11% | -252.16% | 5.65% | 22.26% |
| Income Tax Expense | 2.23M | 1.07M | 579.00K | 433.00K | 486.00K |
| Net Income | 6.03M | -13.26M | -282.24M | 4.06M | 12.66M |
| Net Income Ratio | 3.45% | -8.82% | -252.68% | 5.10% | 21.44% |
| EPS | 0.10 | -0.16 | -4.30 | 0.04 | 0.11 |
| EPS Diluted | 0.07 | -0.16 | -4.30 | 0.04 | 0.11 |
| Weighted Avg Shares Out | 88.20M | 85.39M | 65.58M | 113.05M | 113.05M |
| Weighted Avg Shares Out (Dil) | 129.43M | 85.39M | 65.58M | 113.05M | 113.05M |
The Schall Law Firm Is Investigating Enfusion, Inc. For Possible Securities Fraud And Investors With Losses Should Reach Out
Enfusion Inc Might Have Engaged In Securities Related Improprieties And Impacted Shareholders Are Urged To Contact The Schall Law Firm About An Inquiry
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Enfusion Inc May Have Violated Securities Laws And The Schall Law Firm Seeks Shareholder Participation In An Inquiry
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Clients to Contact the Firm!
Source: https://incomestatements.info
Category: Stock Reports